Drug intelligence / Profile preview

MaaT011

Development stage: Phase 2
Lead developer: MaaT Pharma
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Rectal

Overview

MaaT011 is an autologous fecal microbiota transfer (AFMT) product developed by MaaT Pharma. It is a full-ecosystem microbiome therapeutic manufactured under cGMP conditions, designed to restore gut microbiota diversity and richness in patients undergoing intensive treatments like induction chemotherapy for acute myeloid leukemia (AML). By reintroducing the patient's own pre-treatment microbiome, MaaT011 aims to counteract iatrogenic dysbiosis, reduce the carriage of antibiotic resistance genes, and decrease intestinal inflammation. In the Phase 1/2 ODYSSEE trial, MaaT011 demonstrated proof-of-concept by successfully reestablishing gut microbiota balance and potentially reducing the incidence of gastrointestinal graft-versus-host disease (GI-GvHD) in AML patients following hematopoietic stem cell transplantation. It served as the foundation for the company's subsequent pooled-donor products, MaaT013 and MaaT033.

Other names: Autologous fecal microbiota transferAFMT

Beyond the preview

Go deeper on MaaT011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MaaT011.

Explore the full profile